The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 01, 2022

Filed:

Jan. 22, 2018
Applicant:

Chongqing Upgra Biotechnology Co., Ltd., Chongqing, CN;

Inventors:

Gaoquan Li, Chongqing, CN;

Bin Wang, Chongqing, CN;

Dajun Li, Chongqing, CN;

Qian Zhang, Chongqing, CN;

Lei Huang, Chongqing, CN;

Maofen Chen, Chongqing, CN;

Xiaodan Wu, Chongqing, CN;

Liangyan Peng, Chongqing, CN;

Tingting He, Chongqing, CN;

Yanyan Zhang, Chongqing, CN;

Yun Tang, Chongqing, CN;

Huan Liu, Chongqing, CN;

Jvyuan Shui, Chongqing, CN;

Cuifang Zhang, Chongqing, CN;

Jianhuan Li, Chongqing, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/64 (2017.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01); A61K 31/4184 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 38/05 (2006.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01);
U.S. Cl.
CPC ...
A61K 47/64 (2017.08); A61K 31/4184 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 38/05 (2013.01); A61K 38/06 (2013.01); A61K 38/07 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/542 (2017.08); A61K 47/60 (2017.08); A61P 35/00 (2018.01);
Abstract

Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers.


Find Patent Forward Citations

Loading…